Paris, Monaco XVIth World Meeting of the IUP, August 31st 2009.
Ad Rem Technology Sarl announces today for the XVIth World Meeting of the IUP-InternationalUnion of Phlebology, the results of an important hemodynamic study led by Prof. A. Nicolaidesusing Veinoplus® stimulators.
« We have done more than 4000 measurements and the results are impressive » said Prof.Andrew Nicolaides. «The stimulations triggered by the Veinoplus® allow a very significantenhancement of popliteal blood velocity and volume flow, which are key factors in the preventionof venous stasis and Deep Venous Thrombosis (DVT).
“The OPTIVEIN study aimed to evaluate different signals of stimulation in 12 normal volunteersaccording to 2 criteria: Peak Velocities and Total Volume Flows of expelled blood using duplex-Doppler. The results will be presented shortly at an international scientific meeting.
“We are extremely satisfied with the findings of this study led by Prof. Nicolaides and his teamwhich represent a new step for our technology » added Thierry Tavidian and Pierre-Michel Amiel,Managing Partners of Ad Rem Technology. «The results in terms of enhancement of blood volumeflow expelled by the actual Veinoplus® device available for patients are, to our knowledge,unmatched. The action of Veinoplus® is already clinically proven in the prevention and thetreatment of Venous Insufficiency and this new study clearly widens the potential of the electrostimulationtechnology developed by Dr Cywinski. »
Ad Rem Technology is a French Med-Tech based in Paris and specialized in electro-stimulationapplied to vascular diseases. The first medical device on the market, namely the Veinoplus®,addresses Venous Insufficiency from early symptoms “aching legs” to more severe conditions likepost-thrombotic syndrome (PTS). The Veinoplus® is exported to 15 countries on 5 continents.
DVT is a life-threatening condition which appears when blood is clotting in a vein. DVT can lead topulmonary embolism (PE) and Post-Thrombotic Syndrome (PTS). Annually, it is estimated that inthe USA and in Europe more individuals may die from DVT than from AIDS, breast cancer andmotor vehicles combined.
